Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» UBS analysts weigh in on FDA’s expanded approval of Merck’s Keytruda for the treatment of lung cancer
UBS analysts weigh in on FDA’s expanded approval of Merck’s Keytruda for the treatment of lung cancer
UBS analysts weigh in on FDA’s expanded approval of Merck’s Keytruda for the treatment of lung cancer
Submitted by
admin
on October 7, 2015 - 10:05am
Source:
Bidness, ETC
News Tags:
Merck
non-small cell lung cancer
FDA
Keytruda
Headline:
UBS analysts weigh in on FDA’s expanded approval of Merck’s Keytruda for the treatment of lung cancer
Do Not Allow Advertisers to Use My Personal information
